CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | dipolar compound |
|
Accession: | CHEBI:51151
|
browse the term
|
Definition: | An organic molecule that is electrically neutral carrying a positive and a negative charge in one of its major canonical descriptions. In most dipolar compounds the charges are delocalized; however the term is also applied to species where this is not the case. |
Synonyms: | related_synonym: | dipolar compounds |
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP |
Carnitine results in increased expression of ADIPOQ protein |
CTD |
PMID:30256492 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:29186614 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]] |
CTD |
PMID:33290254 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
EXP |
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA] |
CTD |
PMID:29186614 PMID:36282381 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions increases chemical synthesis |
ISO |
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] |
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA] |
CTD |
PMID:23213347 PMID:29186614 PMID:36282381 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19491382 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]] Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein] |
CTD |
PMID:19491382 PMID:23213347 PMID:26562095 PMID:32478940 PMID:36282381 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein] |
CTD |
PMID:32478940 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein] |
CTD |
PMID:23213347 PMID:32478940 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA] |
CTD |
PMID:16889571 PMID:19294768 PMID:23213347 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26581635 PMID:28973641 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP ISO |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] [Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein] |
CTD |
PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein] |
CTD |
PMID:26581635 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:29710542 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:8130774 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA] |
CTD |
PMID:20470772 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fabp9 |
fatty acid binding protein 9 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein] |
CTD |
PMID:36282381 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein] |
CTD |
PMID:36282381 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23213347 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein] |
CTD |
PMID:32478940 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein] |
CTD |
PMID:16239342 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein] |
CTD |
PMID:22359436 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA] |
CTD |
PMID:26562095 PMID:26581635 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
decreases uptake multiple interactions |
ISO EXP |
INS1 protein results in decreased uptake of Carnitine Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein] |
CTD |
PMID:28298333 PMID:30256492 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein] |
CTD |
PMID:37453608 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of Carnitine |
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
EXP |
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein] |
CTD |
PMID:18597074 PMID:18852009 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA] |
CTD |
PMID:23213347 PMID:33965443 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
EXP |
Carnitine results in increased expression of NOS3 |
CTD |
PMID:20123095 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases activity |
EXP |
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] Carnitine results in increased activity of PPARA protein |
CTD |
PMID:19491382 PMID:19735737 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of PPARG protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein] |
CTD |
PMID:30256492 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgis |
prostaglandin I2 synthase |
increases expression increases response to substance multiple interactions |
EXP |
Carnitine results in increased expression of PTGIS mRNA PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein] |
CTD |
PMID:33965443 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a21 |
solute carrier family 22 (organic cation transporter), member 21 |
multiple interactions increases uptake |
EXP |
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine] |
CTD |
PMID:19735737 |
|
NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
increases uptake |
ISO |
SLC22A4 protein results in increased uptake of Carnitine |
CTD |
PMID:21256917 PMID:33007874 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions decreases expression increases transport increases uptake increases expression affects uptake affects binding |
ISO EXP |
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog SLC22A5 protein affects the uptake of Carnitine Carnitine binds to SLC22A5 protein |
CTD |
PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 PMID:18981167 PMID:19041296 PMID:19539806 PMID:19735737 PMID:20303936 PMID:20470772 PMID:21256917 PMID:21641380 PMID:22701146 PMID:30465787 PMID:31437515 PMID:33007874 PMID:37453608 More...
|
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases transport |
ISO |
SLC22A8 protein results in increased transport of Carnitine |
CTD |
PMID:15100168 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions increases transport |
EXP |
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 PMID:23402788 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of SLC2A4 protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:30256492 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein] |
CTD |
PMID:33965443 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA] |
CTD |
PMID:26562095 PMID:26581635 PMID:28973641 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions decreases expression |
EXP |
Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]] Carnitine results in decreased expression of TNF protein |
CTD |
PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein] |
CTD |
PMID:28973641 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
ISO |
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases phosphorylation |
EXP |
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
multiple interactions |
EXP |
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine |
CTD |
PMID:21296056 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24079413 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Ptafr |
platelet-activating factor receptor |
affects binding multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:16386258 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein] |
CTD |
PMID:24079413 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein |
CTD |
PMID:16386258 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of ALOX12 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA |
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein] |
CTD |
PMID:15149885 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of EGR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein] |
CTD |
PMID:23850278 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression increases secretion multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein] |
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein] |
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Platelet Activating Factor |
CTD |
PMID:10934231 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of MMP13 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein] |
CTD |
PMID:10921504 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21432021 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Platelet Activating Factor results in decreased expression of PPARA mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions increases expression increases phosphorylation affects binding |
ISO EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] |
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvt1 |
Pvt1 oncogene |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] |
CTD |
PMID:32830409 |
|
NCBI chr 7:93,656,528...93,879,938
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein] |
CTD |
PMID:11297424 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of SELE mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
multiple interactions increases secretion |
ISO |
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein] |
CTD |
PMID:9762784 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA] |
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine |
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[NOS1 co-treated with sodium sulfite co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased oxidation of ALB protein |
CTD |
PMID:20348042 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
4'-hydroxydiclofenac promotes the reaction [[Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide]; [[Hydrogen Peroxide results in increased activity of MPO protein] which results in increased oxidation of Glutathione] which results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-anisidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-anisidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-aminobenzonitrile] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-ethylaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of aniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Procainamide] which results in increased expression of MPO protein modified form; [Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-anisidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-anisidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-aminobenzonitrile; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-ethylaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of aniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Procainamide; desmethylnaproxen promotes the reaction [[Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide] |
CTD |
PMID:20199096 PMID:28754375 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
[NOS1 co-treated with sodium sulfite co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased oxidation of ALB protein |
CTD |
PMID:20348042 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
affects binding increases uptake multiple interactions increases transport |
ISO EXP |
pivaloylcarnitine binds to SLC22A5 protein SLC22A5 protein results in increased uptake of pivaloylcarnitine Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine] |
CTD |
PMID:18762717 PMID:19539806 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
decreases expression |
EXP |
L-carnitine decreases expression of Acacb mRNA and protein in rat heart |
RGD |
PMID:30644033 |
RGD:329955369 |
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
EXP |
L-carnitine increases expression of Cpt1a mRNA and protein in rat heart L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
increases expression multiple interactions |
EXP |
L-carnitine increases expression of Mlycd protein in rat heart L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression multiple interactions |
EXP |
L-carnitine increases expression of Ampka2 protein in rat serum and heart L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart] |
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein] |
CTD |
PMID:20932872 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein] |
CTD |
PMID:33580994 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein] |
CTD |
PMID:33580994 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of and results in increased localization of Doxorubicin] Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of Doxorubicin] |
CTD |
PMID:37453608 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:33580994 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
increases expression |
EXP |
Betaine results in increased expression of ABI3BP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO EXP |
Betaine results in decreased expression of AHCY mRNA |
CTD |
PMID:22945834 PMID:26391144 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akip1 |
A-kinase interacting protein 1 |
increases expression |
EXP |
Betaine results in increased expression of AKIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:163,734,730...163,743,648
Ensembl chr 1:163,734,798...163,743,648
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression |
EXP |
Betaine results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein |
CTD |
PMID:20118189 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
Betaine results in decreased expression of APEX1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene |
CTD |
PMID:16868943 |
|
NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
Betaine results in decreased expression of BAX protein |
CTD |
PMID:25080425 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects binding increases expression |
ISO EXP |
Betaine analog binds to BCL2 protein Betaine results in increased expression of BCL2 protein |
CTD |
PMID:25080425 PMID:25765238 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
EXP |
Betaine results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
increases metabolic processing |
ISO |
BHMT protein results in increased metabolism of Betaine |
CTD |
PMID:18230605 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein] |
CTD |
PMID:32418914 |
|
NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Cab39l |
calcium binding protein 39-like |
decreases expression |
EXP |
Betaine results in decreased expression of CAB39L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
|
|
G |
Casp1 |
caspase 1 |
increases expression |
EXP |
Betaine results in increased expression of CASP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein] |
CTD |
PMID:24632105 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein] |
CTD |
PMID:12893363 PMID:20118189 PMID:24632105 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
increases expression |
EXP |
Betaine results in increased expression of CCDC113 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
Betaine results in increased expression of CCL5 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression |
EXP |
Betaine results in increased expression of CCL6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
EXP |
Betaine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
decreases expression |
EXP |
Betaine results in decreased expression of CD44 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
decreases expression |
EXP |
Betaine results in decreased expression of CDC42EP2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897
|
|
G |
Cdh13 |
cadherin 13 |
decreases expression |
EXP |
Betaine results in decreased expression of CDH13 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Ces3a |
carboxylesterase 3a |
increases expression |
EXP |
Betaine results in increased expression of CES3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Ckb |
creatine kinase B |
increases expression |
EXP |
Betaine results in increased expression of CKB mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
decreases expression |
EXP |
Betaine results in decreased expression of CKS1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of COTL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
ISO |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in decreased expression of CPT1A mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
EXP |
Betaine results in decreased expression of CXCL16 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1] |
CTD |
PMID:20118189 PMID:21352821 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
increases expression |
EXP |
Betaine results in increased expression of CYSLTR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of DAPK1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
EXP |
Betaine results in increased expression of DLX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression |
ISO |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in increased expression of DNMT1 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Betaine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ect2 |
epithelial cell transforming 2 |
decreases expression |
EXP |
Betaine results in decreased expression of ECT2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
increases expression |
EXP |
Betaine results in increased expression of EEF2K mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:175,393,119...175,456,756
Ensembl chr 1:175,393,154...175,455,164
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP ISO |
Betaine results in increased expression of EGR1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
decreases expression |
EXP |
Betaine results in decreased expression of ELF3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Emc9 |
ER membrane protein complex subunit 9 |
increases expression |
EXP |
Betaine results in increased expression of EMC9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098
|
|
G |
Ephb6 |
Eph receptor B6 |
increases expression |
EXP |
Betaine results in increased expression of EPHB6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
|
|
G |
F8 |
coagulation factor VIII |
multiple interactions increases secretion |
ISO |
Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form |
CTD |
PMID:22973456 |
|
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
|
|
G |
F9 |
coagulation factor IX |
increases secretion |
ISO |
Betaine results in increased secretion of F9 protein |
CTD |
PMID:22973456 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] |
CTD |
PMID:22648174 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
increases expression |
EXP |
Betaine results in increased expression of FLRT3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
decreases expression |
EXP |
Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form |
CTD |
PMID:26391144 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:19294532 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gna14 |
G protein subunit alpha 14 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression multiple interactions |
EXP ISO |
Betaine results in increased expression of GPCPD1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:19294532 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
H2az1 |
H2A.Z variant histone 1 |
decreases expression |
EXP |
Betaine results in decreased expression of H2AZ1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of HIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hmgb2 |
high mobility group box 2 |
decreases expression |
EXP |
Betaine results in decreased expression of HMGB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Betaine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
Betaine results in increased expression of ID2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Betaine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
EXP |
Betaine results in decreased expression of IRX4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Itga8 |
integrin subunit alpha 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Betaine results in increased expression of JUN mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khdrbs3 |
KH RNA binding domain containing, signal transduction associated 3 |
decreases expression |
EXP |
Betaine results in decreased expression of KHDRBS3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Betaine results in increased expression of KIF1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
EXP |
Betaine results in decreased expression of KIF22 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401
|
|
G |
Klf10 |
KLF transcription factor 10 |
increases expression |
EXP |
Betaine results in increased expression of KLF10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Krt2 |
keratin 2 |
increases expression |
EXP |
Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein |
CTD |
PMID:26391144 |
|
NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963
|
|
G |
Krt4 |
keratin 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Lars1 |
leucyl-tRNA synthetase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of LARS1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lin9 |
lin-9 DREAM MuvB core complex component |
decreases expression |
EXP |
Betaine results in decreased expression of LIN9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:92,374,612...92,419,664
Ensembl chr13:92,374,593...92,419,654
|
|
G |
Lratd1 |
LRAT domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319
|
|
G |
Lrrc24 |
leucine rich repeat containing 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438
|
|
G |
Map4k1 |
mitogen activated protein kinase kinase kinase kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
multiple interactions decreases stability |
ISO |
Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein] |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM7 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mical1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
EXP |
Betaine results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
EXP |
Betaine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycl |
MYCL proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582
|
|
G |
Nbl1 |
NBL1, DAN family BMP antagonist |
increases expression |
EXP |
Betaine results in increased expression of NBL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:151,318,752...151,329,948
Ensembl chr 5:151,318,754...151,338,719
|
|
G |
Nckipsd |
NCK interacting protein with SH3 domain |
decreases expression |
EXP |
Betaine results in decreased expression of NCKIPSD mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:109,511,484...109,522,622
Ensembl chr 8:109,511,658...109,522,246
|
|
G |
Ndrg4 |
NDRG family member 4 |
decreases expression |
EXP |
Betaine results in decreased expression of NDRG4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases expression |
EXP |
Betaine results in decreased expression of NUPR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter] |
CTD |
PMID:22064374 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
increases expression |
EXP |
Betaine results in increased expression of PCP4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
EXP |
Betaine results in decreased expression of PCTP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867
|
|
G |
Per2 |
period circadian regulator 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Pola2 |
DNA polymerase alpha 2, accessory subunit |
decreases expression |
EXP |
Betaine results in decreased expression of POLA2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
decreases expression |
EXP |
Betaine results in decreased expression of POLE2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein Betaine results in decreased expression of PPARA mRNA |
CTD |
PMID:20118189 PMID:22945834 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein] |
CTD |
PMID:32492475 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
EXP |
Betaine results in increased expression of PRSS23 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Prss8 |
serine protease 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of PTGS1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ranbp3l |
RAN binding protein 3-like |
decreases expression |
EXP |
Betaine results in decreased expression of RANBP3L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:58,057,887...58,113,158
Ensembl chr 2:58,058,263...58,113,172
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein] |
CTD |
PMID:25559852 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rfx4 |
regulatory factor X4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Betaine results in increased expression of RGS2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression multiple interactions |
EXP ISO |
Betaine results in decreased expression of RRM2 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
EXP |
Betaine results in decreased expression of SCD1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sectm1b |
secreted and transmembrane 1B |
increases expression |
EXP |
Betaine results in increased expression of SECTM1A mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:106,324,070...106,333,779
Ensembl chr10:106,325,203...106,333,769
|
|
G |
Serinc2 |
serine incorporator 2 |
decreases expression |
EXP |
Betaine results in decreased expression of SERINC2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:142,592,308...142,614,628
Ensembl chr 5:142,592,309...142,618,364
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
decreases expression |
EXP |
Betaine results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression |
EXP |
Betaine results in increased expression of SLC16A6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:16928358 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc25a30 |
solute carrier family 25, member 30 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613
|
|
G |
Slc36a1 |
solute carrier family 36 member 1 |
increases uptake |
ISO |
SLC36A1 protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr10:39,319,062...39,357,374
Ensembl chr10:39,324,337...39,354,217
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA] |
CTD |
PMID:22053950 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G |
Slc6a20a |
solute carrier family 6 member 20a |
increases uptake |
ISO |
SLC6A20B protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
decreases expression |
EXP |
Betaine results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Snx10 |
sorting nexin 10 |
decreases expression |
EXP |
Betaine results in decreased expression of SNX10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sostdc1 |
sclerostin domain containing 1 |
increases expression |
EXP |
Betaine results in increased expression of SOSTDC1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:53,051,336...53,055,510
Ensembl chr 6:53,051,354...53,055,579
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Betaine results in decreased expression of SPC25 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Ssr4 |
signal sequence receptor subunit 4 |
decreases expression |
EXP |
Betaine results in decreased expression of SSR4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:25080425 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression |
EXP |
Betaine results in decreased expression of STMN1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Stxbp1 |
syntaxin binding protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of STXBP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Betaine results in increased expression of TGFB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
decreases expression |
EXP |
Betaine results in decreased expression of TRIB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Upk3bl1 |
uroplakin 3B like 1 |
decreases expression |
EXP |
Betaine results in decreased expression of UPK3BL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:20,610,353...20,616,366
Ensembl chr12:20,610,353...20,616,366
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Wnk4 |
WNK lysine deficient protein kinase 4 |
decreases expression |
EXP |
Betaine results in decreased expression of WNK4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829
|
|
G |
Ybx2 |
Y box binding protein 2 |
decreases expression |
EXP |
Betaine results in decreased expression of YBX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:54,659,719...54,665,371
Ensembl chr10:54,659,719...54,665,371
|
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein] |
CTD |
PMID:32417162 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein] |
CTD |
PMID:32417162 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:32417162 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:32417162 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
EXP ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:27559315 PMID:32389661 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA |
CTD |
PMID:27559315 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
increases uptake |
ISO EXP |
SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate |
CTD |
PMID:18981167 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA |
CTD |
PMID:27559315 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
|
G |
Fxn |
frataxin |
increases expression |
ISO |
Molsidomine results in increased expression of FXN mRNA |
CTD |
PMID:23418481 |
|
NCBI chr 1:221,874,007...221,897,543
Ensembl chr 1:221,872,420...221,897,540
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Molsidomine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Molsidomine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCA1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCB4 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Bezafibrate] results in increased expression of ABCC2 mRNA |
CTD |
PMID:21549692 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCD1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ABCD1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ABCD2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACAA1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACAA1A mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACAA1B mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases phosphorylation increases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased phosphorylation of ACACA protein Sodium Glutamate results in increased expression of ACACA mRNA; Sodium Glutamate results in increased expression of ACACA protein 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine affects the reaction [[Dietary Fats co-treated with Sodium Glutamate] affects the expression of ACACA mRNA]; [Dietary Fats co-treated with Sodium Glutamate] affects the expression of ACACA mRNA; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of ACACA mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of ACACA protein] |
CTD |
PMID:19724016 PMID:22415589 PMID:26670228 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACACB mRNA |
CTD |
PMID:23783067 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACADL mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ACADM mRNA SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of ACADM mRNA] |
CTD |
PMID:19724016 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACADS mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACADS mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACADS mRNA |
CTD |
PMID:19001666 PMID:23783067 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACADVL mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACADVL mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases expression |
EXP |
Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of ACHE protein] Sodium Glutamate results in increased expression of ACHE mRNA |
CTD |
PMID:20928830 PMID:26900785 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACLY mRNA |
CTD |
PMID:19001666 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACO1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of ACO1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ACOT1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ACOT12 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ACOT2 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ACOT2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ACOT4 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ACOT4 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP ISO |
[Taurine co-treated with Sodium Glutamate] results in increased expression of ACOX1 mRNA [Sodium Glutamate co-treated with Bezafibrate] results in increased expression of ACOX1 mRNA |
CTD |
PMID:21549692 PMID:26092479 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acr |
acrosin |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ACR mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 7:120,636,581...120,644,474
Ensembl chr 7:120,638,321...120,644,474
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ACSBG1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ACSF2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ACSL3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acvr2b |
activin A receptor type 2B |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ACVR2B mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Adam5 |
ADAM metallopeptidase domain 5 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ADAM5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:67,223,095...67,298,733
Ensembl chr16:67,223,143...67,298,737
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ADAMTS7 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:90,704,727...90,744,333
Ensembl chr 8:90,704,727...90,744,328
|
|
G |
Adamtsl3 |
ADAMTS-like 3 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ADAMTSL3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:136,288,793...136,596,986
Ensembl chr 1:136,288,793...136,596,986
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ADCY5 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ADGRE1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of ADIPOQ protein [Sodium Glutamate co-treated with Pioglitazone] results in increased expression of ADIPOQ protein; [Sodium Glutamate co-treated with Plant Extracts] results in decreased expression of ADIPOQ mRNA; Bezafibrate inhibits the reaction [Sodium Glutamate results in decreased expression of ADIPOQ protein]; fructooligosaccharide inhibits the reaction [Sodium Glutamate results in decreased expression of ADIPOQ protein] |
CTD |
PMID:21549692 PMID:27918843 PMID:32103741 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ADORA1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ADRA1A mRNA |
CTD |
PMID:19001666 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ADRA1D mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Agrp |
agouti related neuropeptide |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of AGRP mRNA |
CTD |
PMID:19151514 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AHR mRNA |
CTD |
PMID:19001666 PMID:22078008 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm3 |
apoptosis inducing factor, mitochondria associated 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AIFM3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr11:83,504,859...83,523,630
Ensembl chr11:83,504,861...83,521,248
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AKR1A1 mRNA; Sodium Glutamate results in increased expression of AKR1A1 protein |
CTD |
PMID:25473020 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AKR1C6 mRNA |
CTD |
PMID:25473020 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Sodium Glutamate results in decreased phosphorylation of AKT1 protein Tea inhibits the reaction [Sodium Glutamate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:29679905 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of ALDH1A1 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ALDH3A1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Alg6 |
ALG6, alpha-1,3-glucosyltransferase |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ALG6 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions increases expression |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of ALOX15 mRNA; [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ALOX15 mRNA Sodium Glutamate results in increased expression of ALOX15 mRNA |
CTD |
PMID:20111022 PMID:23783067 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Ambra1 |
autophagy and beclin 1 regulator 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AMBRA1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:77,700,936...77,890,221
Ensembl chr 3:77,700,936...77,890,221
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ANXA1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Ap1m2 |
adaptor related protein complex 1 subunit mu 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of AP1M2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 8:19,838,579...19,856,560
Ensembl chr 8:19,838,580...19,856,482
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of APBB1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 1:159,896,889...159,920,505
Ensembl chr 1:159,896,880...159,920,627
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of APMAP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of APOC2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apod |
apolipoprotein D |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of APOD mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of APOD mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Apoe |
apolipoprotein E |
increases expression multiple interactions |
ISO EXP |
Sodium Glutamate results in increased expression of APOE mRNA; Sodium Glutamate results in increased expression of APOE protein 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Sodium Glutamate results in increased expression of APOE mRNA] |
CTD |
PMID:31981724 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ARAP3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr18:29,806,214...29,834,217
Ensembl chr18:29,807,536...29,833,555
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ARC mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ARG2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ARHGEF1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953
|
|
G |
Arsb |
arylsulfatase B |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of ARSB mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of ATP1A3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp2b3 |
ATPase plasma membrane Ca2+ transporting 3 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ATP2B3 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr X:151,216,483...151,289,069
Ensembl chr X:151,216,507...151,286,775
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ATP7B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Axin1 |
axin 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of AXIN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of BAMBI mRNA |
CTD |
PMID:22078008 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of BAX mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of BAX mRNA Sodium Glutamate results in increased expression of BAX mRNA Lycopene inhibits the reaction [Sodium Glutamate results in increased expression of BAX mRNA] |
CTD |
PMID:23783067 PMID:26900785 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bccip |
BRCA2 and CDKN1A interacting protein |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of BCCIP mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of BCCIP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:188,512,544...188,524,957
Ensembl chr 1:188,512,367...188,524,958
|
|
G |
Bche |
butyrylcholinesterase |
increases activity multiple interactions |
EXP |
Sodium Glutamate results in increased activity of BCHE protein Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of BCHE protein] |
CTD |
PMID:26900785 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
EXP ISO |
[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 mRNA; [Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 protein; Folic Acid affects the reaction [[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 mRNA]; Folic Acid affects the reaction [[Homocysteine co-treated with Sodium Glutamate] affects the expression of BCL2 protein]; Lycopene inhibits the reaction [Sodium Glutamate results in decreased expression of BCL2 mRNA] SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of BCL2 mRNA] |
CTD |
PMID:16782274 PMID:22169520 PMID:26900785 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of BCL2L11 mRNA Sodium Glutamate results in increased expression of BCL2L11 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bend3 |
BEN domain containing 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BEND3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:46,980,246...47,017,059
Ensembl chr20:46,979,831...47,014,671
|
|
G |
Bin3 |
bridging integrator 3 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of BIN3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
multiple interactions increases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of BMI1 mRNA Sodium Glutamate results in increased expression of BMI1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Bnip5 |
BCL2 interacting protein 5 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BNIP5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:6,957,736...6,975,062
Ensembl chr20:6,956,201...6,975,091
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BOP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:108,172,062...108,195,875
Ensembl chr 7:108,172,066...108,195,931
|
|
G |
Brsk2 |
BR serine/threonine kinase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BRSK2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:197,035,505...197,088,624
Ensembl chr 1:197,035,633...197,088,092
|
|
G |
Bzw2 |
basic leucine zipper and W2 domains 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of BZW2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:52,828,069...52,888,599
Ensembl chr 6:52,827,661...52,888,628
|
|
G |
C1qtnf1 |
C1q and TNF related 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of C1QTNF1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:103,660,319...103,681,662
Ensembl chr10:103,660,327...103,681,660
|
|
G |
Cabp2 |
calcium binding protein 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CABP2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CABP2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:201,374,649...201,380,469
Ensembl chr 1:201,375,276...201,380,469
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA1A mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNA1A mRNA |
CTD |
PMID:23783067 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA1I mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNA1I mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d4 |
calcium voltage-gated channel auxiliary subunit alpha2delta 4 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNA2D4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNA2D4 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 4:152,408,588...152,521,478
Ensembl chr 4:152,408,657...152,521,268
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNB2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNB2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106
|
|
G |
Cacng4 |
calcium voltage-gated channel auxiliary subunit gamma 4 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNG4 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNG4 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:92,683,778...92,745,842
Ensembl chr10:92,683,761...92,746,126
|
|
G |
Cacng8 |
calcium voltage-gated channel auxiliary subunit gamma 8 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CACNG8 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CACNG8 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:65,755,334...65,775,567
Ensembl chr 1:65,755,334...65,779,089
|
|
G |
Calhm2 |
calcium homeostasis modulator family member 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CALHM2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CALHM2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:246,022,324...246,028,050
Ensembl chr 1:246,022,324...246,028,218
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CALR mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calr3 |
calreticulin 3 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CALR3 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CALR3 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr16:17,396,064...17,423,166
Ensembl chr16:17,396,247...17,423,015
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
increases expression |
EXP |
Sodium Glutamate results in increased expression of CAMK2A mRNA |
CTD |
PMID:20928830 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CAMK2B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camlg |
calcium modulating ligand |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CAMLG mRNA |
CTD |
PMID:20928830 |
|
NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552
|
|
G |
Cant1 |
calcium activated nucleotidase 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CANT1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CANT1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109
|
|
G |
Caps2 |
calcyphosine 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CAPS2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:47,580,636...47,641,598
Ensembl chr 7:47,581,137...47,639,229
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CAR2 mRNA |
CTD |
PMID:31569818 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car5b |
carbonic anhydrase 5B |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CAR5B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr X:30,474,697...30,534,797
Ensembl chr X:30,474,784...30,533,837
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CASP6 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CASP9 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CASP9 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression increases expression multiple interactions increases activity decreases activity |
ISO EXP |
Sodium Glutamate results in decreased expression of CAT mRNA Sodium Glutamate results in increased expression of CAT mRNA; Sodium Glutamate results in increased expression of CAT protein [Plant Extracts co-treated with Sodium Glutamate] results in increased activity of CAT protein; Sodium Glutamate results in increased expression of and results in decreased activity of CAT protein; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CAT mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CAT protein]; Tea inhibits the reaction [Sodium Glutamate results in decreased activity of CAT protein] Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of CAT protein]; Lycopene inhibits the reaction [Sodium Glutamate results in increased expression of CAT mRNA] |
CTD |
PMID:19724016 PMID:25473020 PMID:26319613 PMID:26900785 PMID:29679905 PMID:30733785 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Catsper1 |
cation channel, sperm associated 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CATSPER1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:202,643,009...202,652,059
Ensembl chr 1:202,643,038...202,651,824
|
|
G |
Catsper2 |
cation channel, sperm associated 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CATSPER2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:108,368,654...108,389,380
Ensembl chr 3:108,368,668...108,388,050
|
|
G |
Cbr1 |
carbonyl reductase 1 |
increases activity |
ISO |
Sodium Glutamate results in increased activity of CBR1 protein |
CTD |
PMID:25473020 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Ccdc138 |
coiled-coil domain containing 138 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC138 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:26,493,624...26,572,367
Ensembl chr20:26,495,235...26,572,376
|
|
G |
Ccdc30 |
coiled-coil domain containing 30 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC30 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:132,926,767...133,019,635
Ensembl chr 5:132,926,615...133,019,659
|
|
G |
Ccdc39 |
coiled-coil domain containing 39 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC39 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:116,665,651...116,703,354
Ensembl chr 2:116,665,261...116,703,350
|
|
G |
Ccdc60 |
coiled-coil domain containing 60 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CCDC60 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:40,314,687...40,480,338
Ensembl chr12:40,314,713...40,480,225
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression increases expression |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate] results in increased expression of CCL2 protein; [Sodium Glutamate co-treated with Aspartame] inhibits the reaction [Fats, Unsaturated results in increased expression of CCL2 protein]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CCL2 mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CCL2 protein] Sodium Glutamate results in decreased expression of CCL2 mRNA Sodium Glutamate results in increased expression of CCL2 mRNA; Sodium Glutamate results in increased expression of CCL2 protein |
CTD |
PMID:19724016 PMID:20111022 PMID:23783067 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in decreased expression of CCL21A mRNA Sodium Glutamate results in increased expression of CCL21A mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccnd2 |
cyclin D2 |
affects expression multiple interactions |
EXP ISO |
Sodium Glutamate affects the expression of CCND2 mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CCND2 mRNA |
CTD |
PMID:19001666 PMID:28954212 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression increases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of CCND3 mRNA Sodium Glutamate results in increased expression of CCND3 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CCND3 mRNA |
CTD |
PMID:20111022 PMID:22078008 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CCNG1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of CD80 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd81 |
Cd81 molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CD81 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of CD86 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdcp2 |
CUB domain containing protein 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CDCP2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:121,877,581...121,894,203
Ensembl chr 5:121,877,581...121,894,203
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CDH1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CDK5 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] affects the expression of CDKN1A mRNA |
CTD |
PMID:19001666 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CDKN1B mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression increases expression |
EXP ISO |
Sodium Glutamate results in decreased expression of CDKN2A mRNA; Sodium Glutamate results in decreased expression of CDKN2A protein Sodium Glutamate results in increased expression of CDKN2A mRNA |
CTD |
PMID:22078008 PMID:28954212 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in increased expression of CDKN2B mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CDKN2B mRNA |
CTD |
PMID:19001666 PMID:28954212 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CDKN2D mRNA |
CTD |
PMID:28954212 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CDS1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
|
|
G |
Cep76 |
centrosomal protein 76 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CEP76 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr18:61,174,514...61,208,512
Ensembl chr18:61,178,310...61,208,504
|
|
G |
Cfd |
complement factor D |
multiple interactions decreases activity decreases expression |
ISO |
[Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD mRNA]; [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD protein]; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CFD mRNA Sodium Glutamate results in decreased activity of CFD protein Sodium Glutamate results in decreased expression of CFD mRNA; Sodium Glutamate results in decreased expression of CFD protein |
CTD |
PMID:2307116 PMID:2734615 PMID:2798420 PMID:3299706 PMID:7961801 PMID:19001666 More...
|
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
EXP |
Sodium Glutamate inhibits the reaction [CGA protein results in increased secretion of 7-hydroxyprogesterone]; Sodium Glutamate inhibits the reaction [CGA protein results in increased secretion of Androstenedione] |
CTD |
PMID:14657608 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CHERP mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CHERP mRNA |
CTD |
PMID:23783067 |
|
NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507
|
|
G |
Chmp5 |
charged multivesicular body protein 5 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CHMP5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CHRNB3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CHST1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression increases phosphorylation multiple interactions |
EXP ISO |
Sodium Glutamate results in decreased expression of CHUK mRNA Sodium Glutamate results in increased phosphorylation of CHUK protein Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19800637 PMID:28954212 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciao2a |
cytosolic iron-sulfur assembly component 2A |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CIAO2A mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:66,670,533...66,682,455
Ensembl chr 8:66,670,483...66,682,455
|
|
G |
Ciart |
circadian associated repressor of transcription |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CIART mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CIDEA mRNA |
CTD |
PMID:19001666 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CIDEC mRNA Sodium Glutamate results in increased expression of CIDEC mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Ckb |
creatine kinase B |
increases activity multiple interactions |
EXP |
Sodium Glutamate results in increased activity of CKB protein Lycopene inhibits the reaction [Sodium Glutamate results in increased activity of CKB protein] |
CTD |
PMID:26900785 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clspn |
claspin |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CLSPN mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:138,850,119...138,885,037
Ensembl chr 5:138,850,128...138,885,034
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CLSTN3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmc1 |
C-x(9)-C motif containing 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CMC1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CMC1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 8:117,798,036...117,900,458
Ensembl chr 8:117,798,945...117,900,462
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CMKLR1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:42,974,462...43,027,321
Ensembl chr12:42,974,410...43,028,129
|
|
G |
Cnih4 |
cornichon family AMPA receptor auxiliary protein 4 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CNIH4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr13:92,910,315...92,926,428
Ensembl chr13:92,910,315...92,927,853
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CNNM3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
|
|
G |
Coa7 |
cytochrome c oxidase assembly factor 7 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of COA7 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of COL1A1 mRNA |
CTD |
PMID:28954212 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of COL3A1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Comp |
cartilage oligomeric matrix protein |
decreases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of COMP mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of COMP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr16:19,047,206...19,055,584
Ensembl chr16:19,047,207...19,055,845
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of COMT mRNA |
CTD |
PMID:22078008 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
multiple interactions increases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of COPS3 mRNA Sodium Glutamate results in increased expression of COPS3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Coq10b |
coenzyme Q10B |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of COQ10B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of COTL1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cox11 |
cytochrome c oxidase copper chaperone COX11 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of COX11 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of COX11 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr10:75,458,735...75,465,322
Ensembl chr10:75,458,749...75,465,322
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4i2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of COX4I2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 3:141,228,443...141,239,337
Ensembl chr 3:141,228,443...141,239,331
|
|
G |
Cox7a1 |
cytochrome c oxidase subunit 7A1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of COX7A1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of COX7A1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
increases expression |
ISO |
Sodium Glutamate results in increased expression of COX7A2L mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 6:11,184,064...11,198,287
Ensembl chr 6:11,184,285...11,198,273
|
|
G |
Cpne2 |
copine 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CPNE2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:10,434,277...10,472,146
Ensembl chr19:10,434,277...10,471,820
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
EXP ISO |
Taurine inhibits the reaction [Sodium Glutamate results in decreased expression of CPT1A mRNA] [Sodium Glutamate co-treated with Bezafibrate] results in increased expression of CPT1A mRNA |
CTD |
PMID:21549692 PMID:26092479 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions increases expression |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CPT1B mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of CPT1B mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CPT1B mRNA; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of CPT1B mRNA] |
CTD |
PMID:19001666 PMID:19724016 PMID:23783067 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CPT1C mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CPT2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cpz |
carboxypeptidase Z |
increases expression |
EXP |
Sodium Glutamate results in increased expression of CPZ mRNA |
CTD |
PMID:20928830 |
|
NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Crat |
carnitine O-acetyltransferase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CRAT mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
affects expression increases expression multiple interactions decreases phosphorylation |
EXP ISO |
Sodium Glutamate affects the expression of CREB1 mRNA Sodium Glutamate results in increased expression of CREB1 mRNA 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Sodium Glutamate results in increased expression of CREB1 mRNA]; Dizocilpine Maleate inhibits the reaction [Sodium Glutamate results in increased expression of CREB1 mRNA] [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CREB1 mRNA Sodium Glutamate results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:23783067 PMID:28954212 PMID:31981724 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CREBBP mRNA |
CTD |
PMID:28954212 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Creld2 |
cysteine-rich with EGF-like domains 2 |
multiple interactions decreases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of CRELD2 mRNA Sodium Glutamate results in decreased expression of CRELD2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of CRH mRNA |
CTD |
PMID:8071649 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crtam |
cytotoxic and regulatory T cell molecule |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CRTAM mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:41,340,117...41,377,381
Ensembl chr 8:41,340,837...41,377,343
|
|
G |
Crtap |
cartilage associated protein |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CRTAP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of CRY1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Crybg1 |
crystallin beta-gamma domain containing 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CRYBG1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of CSF1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
[EPO protein co-treated with Sodium Glutamate] affects the expression of CSF2RB mRNA |
CTD |
PMID:30837834 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CTRB1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:33,827,279...33,829,129
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CX3CR1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CXCL9 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyb5b |
cytochrome b5 type B |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CYB5B mRNA |
CTD |
PMID:19001666 |
|
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP1A2 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP1A2 mRNA |
CTD |
PMID:25663641 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp20a1 |
cytochrome P450, family 20, subfamily a, polypeptide 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of CYP20A1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:61,755,804...61,805,123
Ensembl chr 9:61,755,790...61,805,123
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Sodium Glutamate results in increased expression of and results in increased activity of CYP2A1 protein |
CTD |
PMID:7476908 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Sodium Glutamate results in decreased expression of and results in decreased activity of CYP2A2 protein |
CTD |
PMID:7476908 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2B10 mRNA; [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2B10 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2B10 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of CYP2B10 mRNA Sodium Glutamate results in increased expression of CYP2B10 mRNA |
CTD |
PMID:19001666 PMID:20111022 PMID:25663641 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions decreases expression decreases activity increases expression |
EXP |
[Sodium Glutamate co-treated with GH1 protein] results in decreased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased ubiquitination of CYP2C11 protein; GH1 protein affects the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; GH1 protein affects the reaction [Sodium Glutamate results in decreased expression of CYP2C11 mRNA]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of CYP2C11 protein]; Sodium Glutamate results in increased expression of and affects the splicing of CYP2C11 mRNA alternative form; Sodium Glutamate results in increased expression of and results in decreased splicing of CYP2C11 mRNA; Sodium Glutamate results in increased expression of and results in increased activity of CYP2C11 protein Sodium Glutamate results in increased expression of CYP2C11 mRNA; Sodium Glutamate results in increased expression of CYP2C11 mRNA alternative form; Sodium Glutamate results in increased expression of CYP2C11 protein |
CTD |
PMID:7476908 PMID:7965769 PMID:8496838 PMID:11089541 PMID:25697375 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c12 |
cytochrome P450, family 2, subfamily c, polypeptide 12 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of CYP2C12 mRNA; Sodium Glutamate results in increased expression of CYP2C12 protein |
CTD |
PMID:8010984 |
|
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2C55 mRNA Sodium Glutamate results in increased expression of CYP2C55 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2C66 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2C9 mRNA Sodium Glutamate results in increased expression of CYP2C66 mRNA |
CTD |
PMID:20111022 PMID:25663641 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2C29 mRNA Sodium Glutamate results in increased expression of CYP2C29 mRNA |
CTD |
PMID:20111022 PMID:25663641 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2D22 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2D22 mRNA |
CTD |
PMID:25663641 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP2E1 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP2E1 mRNA |
CTD |
PMID:25663641 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
GH1 protein inhibits the reaction [Sodium Glutamate results in decreased expression of and results in decreased activity of CYP3A2 protein]; Sodium Glutamate results in decreased expression of and results in decreased activity of CYP3A2 protein |
CTD |
PMID:7476908 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions decreases expression |
ISO EXP |
[Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA; [Sodium Glutamate co-treated with Tea] affects the expression of CYP3A13 mRNA Sodium Glutamate results in decreased expression of CYP3A9 mRNA |
CTD |
PMID:20928830 PMID:25663641 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO EXP |
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Sodium Glutamate results in increased expression of CYP46A1 mRNA]; Dizocilpine Maleate inhibits the reaction [Sodium Glutamate results in increased expression of CYP46A1 mRNA]; Dizocilpine Maleate inhibits the reaction [Sodium Glutamate results in increased expression of CYP46A1 protein] Sodium Glutamate results in increased expression of CYP46A1 mRNA; Sodium Glutamate results in increased expression of CYP46A1 protein |
CTD |
PMID:31981724 |
|
NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP7A1 mRNA Sodium Glutamate results in increased expression of CYP7A1 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dbndd1 |
dysbindin domain containing 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DBNDD1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:51,539,154...51,548,441
Ensembl chr19:51,539,148...51,548,444
|
|
G |
Dctn1 |
dynactin subunit 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of DCTN1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 4:115,671,024...115,703,824
Ensembl chr 4:115,661,638...115,703,815
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DCXR mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Ddx19b |
DEAD-box helicase 19B |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DDX19B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:38,968,215...38,998,907
Ensembl chr19:38,968,215...38,997,259
|
|
G |
Defb1 |
defensin beta 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of DEFB1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604
|
|
G |
Depdc1b |
DEP domain containing 1B |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of DEPDC1B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dglucy |
D-glutamate cyclase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of DGLUCY mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 6:120,055,480...120,130,910
Ensembl chr 6:120,055,460...120,130,910
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of DIABLO mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of DIABLO mRNA |
CTD |
PMID:23783067 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of DLK1 mRNA |
CTD |
PMID:28954212 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of DLX5 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of DNAJA1 mRNA [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of DNAJA1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnajc27 |
DnaJ heat shock protein family (Hsp40) member C27 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of DNAJC27 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of DNAJC27 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 6:27,068,713...27,098,449
Ensembl chr 6:27,068,686...27,098,449
|
|
G |
Dnal1 |
dynein, axonemal, light chain 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DNAL1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:103,747,801...103,779,015
Ensembl chr 6:103,747,753...103,778,878
|
|
G |
Dolpp1 |
dolichyldiphosphatase 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of DOLPP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:13,666,000...13,674,312
Ensembl chr 3:13,665,823...13,674,311
|
|
G |
Dpys |
dihydropyrimidinase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DPYS mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:70,822,648...70,929,255
Ensembl chr 7:70,835,789...70,929,231
|
|
G |
Dsp |
desmoplakin |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of DSP mRNA Sodium Glutamate results in increased expression of DSP mRNA |
CTD |
PMID:19001666 |
|
NCBI chr17:26,623,602...26,671,692
Ensembl chr17:26,623,588...26,671,800
|
|
G |
Duox2 |
dual oxidase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DUOX2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of DYNLT3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of DZIP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr15:95,956,329...96,009,994
Ensembl chr15:95,956,398...96,010,066
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of E2F1 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of E2F1 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of E2F3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
Ecel1 |
endothelin converting enzyme-like 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of ECEL1 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 9:87,819,516...87,829,154
Ensembl chr 9:87,816,718...87,826,675
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of ECH1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Efna1 |
ephrin A1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of EFNA1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression multiple interactions |
EXP ISO |
Sodium Glutamate results in decreased expression of EGFR mRNA [Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of EGFR mRNA |
CTD |
PMID:19001666 PMID:28954212 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of EHHADH mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of EHHADH mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of EHHADH mRNA |
CTD |
PMID:19001666 PMID:23783067 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Eif2ak4 |
eukaryotic translation initiation factor 2 alpha kinase 4 |
multiple interactions increases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of EIF2AK4 mRNA Sodium Glutamate results in increased expression of EIF2AK4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 3:105,356,261...105,441,630
Ensembl chr 3:105,356,261...105,441,630
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of EIF4EBP2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:29,379,444...29,400,110
Ensembl chr20:29,382,668...29,399,946
|
|
G |
Elane |
elastase, neutrophil expressed |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ELANE mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Elmo3 |
engulfment and cell motility 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ELMO3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:33,181,952...33,186,399
Ensembl chr19:33,182,036...33,186,410
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine affects the reaction [[Dietary Fats co-treated with Sodium Glutamate] affects the expression of ELOVL6 mRNA]; [Dietary Fats co-treated with Sodium Glutamate] affects the expression of ELOVL6 mRNA |
CTD |
PMID:26670228 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of EMILIN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:25,455,974...25,463,713
Ensembl chr 6:25,445,298...25,463,698
|
|
G |
Emp1 |
epithelial membrane protein 1 |
multiple interactions decreases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of EMP1 mRNA Sodium Glutamate results in decreased expression of EMP1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of EPHX2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of EPHX2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Epo |
erythropoietin |
increases expression multiple interactions affects expression |
EXP ISO |
Sodium Glutamate results in increased expression of EPO mRNA [EPO protein co-treated with Sodium Glutamate] affects the expression of CSF2RB mRNA; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPO protein; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR mRNA; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR protein; EPO protein inhibits the reaction [Sodium Glutamate results in increased expression of EPO mRNA] Sodium Glutamate affects the expression of EPO protein |
CTD |
PMID:30837834 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions increases expression |
ISO EXP |
[EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR mRNA; [EPO protein co-treated with Sodium Glutamate] results in increased expression of EPOR protein Sodium Glutamate results in increased expression of EPOR protein |
CTD |
PMID:30837834 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of ERBB3 mRNA Sodium Glutamate results in increased expression of ERBB3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erlin1 |
ER lipid raft associated 1 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of ERLIN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:242,921,147...242,956,472
Ensembl chr 1:242,921,152...242,956,394
|
|
G |
Esrrb |
estrogen-related receptor beta |
increases expression |
ISO |
Sodium Glutamate results in increased expression of ESRRB mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 6:106,007,701...106,163,136
Ensembl chr 6:106,008,095...106,160,791
|
|
G |
Exosc8 |
exosome component 8 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of EXOSC8 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in decreased expression of EZH1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
Faap24 |
FA core complex associated protein 24 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FAAP24 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:88,051,523...88,057,997
Ensembl chr 1:88,051,911...88,057,989
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FABP5 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FADS1 mRNA Sodium Glutamate results in increased expression of FADS1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FADS2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of FAIM mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
|
|
G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FAIM2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168
|
|
G |
Fam78b |
family with sequence similarity 78, member B |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FAM78B mRNA |
CTD |
PMID:22078008 |
|
NCBI chr13:79,162,393...79,250,958
Ensembl chr13:79,162,228...79,250,500
|
|
G |
Fan1 |
FANCD2 and FANCI associated nuclease 1 |
affects methylation |
EXP |
Sodium Glutamate affects the methylation of FAN1 gene |
CTD |
PMID:29381301 |
|
NCBI chr 1:117,915,323...117,945,044
Ensembl chr 1:117,917,099...117,944,977
|
|
G |
Faslg |
Fas ligand |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of FASL mRNA SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of FASL mRNA] |
CTD |
PMID:16782274 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions increases expression |
ISO EXP |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FASN mRNA; fructooligosaccharide inhibits the reaction [Sodium Glutamate results in increased expression of FASN mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of FASN mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of FASN protein] Sodium Glutamate results in increased expression of FASN mRNA; Sodium Glutamate results in increased expression of FASN protein |
CTD |
PMID:19001666 PMID:19724016 PMID:26092479 PMID:32103741 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of FAT3 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 8:12,691,470...13,274,336
Ensembl chr 8:12,694,019...13,273,135
|
|
G |
Fbln1 |
fibulin 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FBLN1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbn2 |
fibrillin 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FBN2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr18:51,499,670...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Fbxo15 |
F-box protein 15 |
affects methylation |
EXP |
Sodium Glutamate affects the methylation of FBXO15 gene |
CTD |
PMID:29381301 |
|
NCBI chr18:78,319,577...78,634,695
Ensembl chr18:78,319,534...78,390,765
|
|
G |
Fbxo41 |
F-box protein 41 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FBXO41 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 4:118,007,517...118,039,547
Ensembl chr 4:118,010,978...118,039,406
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FDPS mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF21 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF8 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FGFR2 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of FLT1 protein |
CTD |
PMID:28755050 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases expression multiple interactions |
ISO |
Sodium Glutamate results in increased expression of FMO2 mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of FMO2 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FMO2 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Fmod |
fibromodulin |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FMOD mRNA |
CTD |
PMID:19001666 |
|
NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FOLR2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Sodium Glutamate results in decreased expression of FOS mRNA |
CTD |
PMID:28954212 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxb2 |
forkhead box B2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FOXB2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:214,232,731...214,234,226
Ensembl chr 1:214,232,731...214,234,226
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of FOXO3 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp4 |
forkhead box P4 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of FOXP4 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 9:13,058,506...13,115,406
Ensembl chr 9:13,058,476...13,114,879
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases secretion |
ISO |
Sodium Glutamate results in decreased secretion of FSHB protein |
CTD |
PMID:30733785 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Ftcd |
formimidoyltransferase cyclodeaminase |
increases expression |
ISO |
Sodium Glutamate results in increased expression of FTCD mRNA |
CTD |
PMID:22078008 |
|
NCBI chr20:12,055,203...12,068,717
Ensembl chr20:12,055,208...12,068,735
|
|
G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of FXYD6 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of G0S2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of G6PDX mRNA |
CTD |
PMID:19001666 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
increases expression decreases expression |
EXP |
Sodium Glutamate results in increased expression of GAD1 protein Sodium Glutamate results in decreased expression of GAD1 mRNA |
CTD |
PMID:19733649 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
affects expression increases expression decreases expression |
EXP |
Sodium Glutamate affects the expression of GAD2 protein Sodium Glutamate results in increased expression of GAD2 mRNA Sodium Glutamate results in decreased expression of GAD2 protein |
CTD |
PMID:19733649 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions increases expression |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of GADD45B mRNA; [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GADD45B mRNA Sodium Glutamate results in increased expression of GADD45B mRNA |
CTD |
PMID:19001666 PMID:20111022 PMID:23783067 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GALE mRNA |
CTD |
PMID:19001666 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GALK1 mRNA; [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GALK1 mRNA Sodium Glutamate results in increased expression of GALK1 mRNA |
CTD |
PMID:19001666 PMID:20111022 |
|
NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GALNT10 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
|
|
G |
Galp |
galanin-like peptide |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GALP mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269
|
|
G |
Gas2l1 |
growth arrest-specific 2 like 1 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GAS2L1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr14:79,955,350...79,961,830
Ensembl chr14:79,950,555...79,961,438
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GBE1 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
|
|
G |
Gdpd5 |
glycerophosphodiester phosphodiesterase domain containing 5 |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GDPD5 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 1:153,679,718...153,761,452
Ensembl chr 1:153,679,718...153,761,446
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GFAP mRNA |
CTD |
PMID:20928830 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gfm2 |
GTP dependent ribosome recycling factor mitochondrial 2 |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of GFM2 mRNA; [Fats, Unsaturated co-treated with Sodium Glutamate] affects the expression of GFM2 mRNA |
CTD |
PMID:23783067 |
|
NCBI chr 2:28,449,452...28,488,200
Ensembl chr 2:28,449,517...28,488,197
|
|
G |
Gfod2 |
Gfo/Idh/MocA-like oxidoreductase domain containing 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GFOD2 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr19:33,599,689...33,647,060
Ensembl chr19:33,604,187...33,647,004
|
|
G |
Gh1 |
growth hormone 1 |
affects expression decreases expression decreases secretion multiple interactions |
EXP |
Sodium Glutamate affects the expression of GH1 protein Sodium Glutamate results in decreased expression of GH1 mRNA; Sodium Glutamate results in decreased expression of GH1 protein Sodium Glutamate results in decreased secretion of GH1 protein [Octreotide co-treated with Sodium Glutamate] results in decreased expression of and results in decreased secretion of GH1 protein; [Sodium Glutamate co-treated with GH1 protein] results in decreased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased splicing of CYP2C11 mRNA; [Sodium Glutamate co-treated with GH1 protein] results in increased ubiquitination of CYP2C11 protein; GH1 protein affects the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; GH1 protein affects the reaction [Sodium Glutamate results in decreased expression of CYP2C11 mRNA]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased activity of CYP2C11 protein]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased expression of and results in decreased activity of CYP3A2 protein]; GH1 protein inhibits the reaction [Sodium Glutamate results in decreased expression of IGF1 mRNA]; GH1 protein inhibits the reaction [Sodium Glutamate results in increased expression of IGF1R mRNA]; GHRH protein affects the reaction [Sodium Glutamate results in decreased expression of GH1 mRNA]; JI-38 inhibits the reaction [Sodium Glutamate results in decreased secretion of GH1 protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in decreased expression of SOCS2 mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of CYP2C11 protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR protein]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of SOCS2 mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of SOCS2 protein]; Sodium Glutamate inhibits the reaction [GHRL protein results in increased secretion of GH1 protein]; Sodium Glutamate results in decreased expression of and results in decreased secretion of GH1 protein |
CTD |
PMID:7476908 PMID:7711889 PMID:8368293 PMID:8496838 PMID:9053782 PMID:10718930 PMID:12193538 PMID:25697375 More...
|
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghdc |
GH3 domain containing |
decreases expression |
ISO |
Sodium Glutamate results in decreased expression of GHDC mRNA |
CTD |
PMID:22078008 |
|
NCBI chr10:85,693,612...85,697,833
Ensembl chr10:85,693,616...85,697,865
|
|
G |
Ghr |
growth hormone receptor |
increases expression multiple interactions |
EXP |
Sodium Glutamate results in increased expression of GHR mRNA; Sodium Glutamate results in increased expression of GHR protein Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR mRNA]; Sodium Glutamate inhibits the reaction [GH1 protein results in increased expression of GHR protein] |
CTD |
PMID:25697375 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions decreases expression |
EXP |
[Sodium Glutamate co-treated with Octreotide] results in decreased expression of GHRH mRNA; GHRH protein affects the reaction [Sodium Glutamate results in decreased expression of GH1 mRNA] Sodium Glutamate results in decreased expression of GHRH mRNA |
CTD |
PMID:2004597 PMID:8368293 PMID:9053782 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Ghrhr |
growth hormone releasing hormone receptor |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GHRHR mRNA |
CTD |
PMID:10718930 |
|
NCBI chr 4:84,498,159...84,532,851
Ensembl chr 4:84,500,212...84,532,776
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
Sodium Glutamate inhibits the reaction [GHRL protein results in increased secretion of GH1 protein] |
CTD |
PMID:12193538 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Ghsr |
growth hormone secretagogue receptor |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GHSR mRNA |
CTD |
PMID:10718930 |
|
NCBI chr 2:110,268,489...110,271,865
Ensembl chr 2:110,268,489...110,271,865
|
|
G |
Gigyf1 |
GRB10 interacting GYF protein 1 |
multiple interactions increases expression |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of GIGYF1 mRNA Sodium Glutamate results in increased expression of GIGYF1 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:19,166,070...19,181,570
Ensembl chr12:19,166,088...19,175,023
|
|
G |
Gip |
gastric inhibitory polypeptide |
multiple interactions |
ISO |
[Fats, Unsaturated co-treated with Sodium Glutamate] results in increased expression of GIP protein; Sodium Glutamate inhibits the reaction [Aspartame promotes the reaction [Fats, Unsaturated results in increased expression of GIP protein]] |
CTD |
PMID:23783067 |
|
NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503
|
|
G |
Gk |
glycerol kinase |
multiple interactions increases expression |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in decreased expression of GK mRNA Sodium Glutamate results in increased expression of GK mRNA |
CTD |
PMID:19001666 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Glrx |
glutaredoxin |
decreases expression multiple interactions increases expression |
ISO |
Sodium Glutamate results in decreased expression of GLRX mRNA [Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GLRX mRNA Sodium Glutamate results in increased expression of GLRX mRNA |
CTD |
PMID:20111022 PMID:22078008 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
EXP |
Sodium Glutamate results in decreased expression of and results in decreased activity of GLUD1 protein |
CTD |
PMID:11807584 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gmeb2 |
glucocorticoid modulatory element binding protein 2 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GMEB2 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr 3:168,362,650...168,400,788
Ensembl chr 3:168,362,650...168,400,788
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of GMFB mRNA |
CTD |
PMID:22078008 |
|
NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gnpat |
glyceronephosphate O-acyltransferase |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GNPAT mRNA |
CTD |
PMID:19001666 |
|
NCBI chr19:52,822,326...52,848,872
Ensembl chr19:52,822,319...52,852,361
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in decreased expression of GOT1 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of GPAT3 mRNA |
CTD |
PMID:19001666 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpc2 |
glypican 2 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GPC2 mRNA |
CTD |
PMID:20928830 |
|
NCBI chr12:17,277,875...17,284,297
Ensembl chr12:17,277,875...17,284,208
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GPR85 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G |
Gprc5c |
G protein-coupled receptor, class C, group 5, member C |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GPRC5C mRNA |
CTD |
PMID:19001666 |
|
NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression decreases expression increases activity multiple interactions |
ISO |
Sodium Glutamate results in increased expression of GPT protein Sodium Glutamate results in decreased expression of GPT protein Sodium Glutamate results in increased activity of GPT protein 2-ethoxy-3-(4-(2-(4-trifluoromethanesulfonyloxyphenyl)ethoxy)phenyl)propionic acid promotes the reaction [Sodium Glutamate results in increased activity of GPT protein]; 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine affects the reaction [[Dietary Fats co-treated with Sodium Glutamate] affects the expression of GPT protein]; [Dietary Fats co-treated with Sodium Glutamate] affects the expression of GPT protein; Bezafibrate promotes the reaction [Sodium Glutamate results in increased expression of GPT protein]; fructooligosaccharide inhibits the reaction [Sodium Glutamate results in increased expression of GPT protein]; Rosiglitazone promotes the reaction [Sodium Glutamate results in increased activity of GPT protein] |
CTD |
PMID:18048028 PMID:19724016 PMID:21205225 PMID:21549692 PMID:26670228 PMID:32103741 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression increases expression multiple interactions |
ISO |
Sodium Glutamate results in decreased expression of GPX1 mRNA Sodium Glutamate results in increased expression of GPX1 mRNA; Sodium Glutamate results in increased expression of GPX1 protein SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of GPX1 mRNA]; SRT1720 inhibits the reaction [Sodium Glutamate results in increased expression of GPX1 protein] |
CTD |
PMID:19724016 PMID:30733785 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression affects expression |
ISO |
Sodium Glutamate results in decreased expression of GPX2 protein Sodium Glutamate affects the expression of GPX2 mRNA |
CTD |
PMID:25473020 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
affects expression multiple interactions |
ISO EXP |
Sodium Glutamate affects the expression of GRIA2 protein SB 203580 affects the reaction [Sodium Glutamate affects the expression of GRIA2] |
CTD |
PMID:15139026 PMID:16782274 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grifin |
galectin-related inter-fiber protein |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GRIFIN mRNA |
CTD |
PMID:22078008 |
|
NCBI chr12:14,080,170...14,082,892
Ensembl chr12:14,080,910...14,082,877
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GRIK3 mRNA |
CTD |
PMID:22078008 |
|
NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions |
ISO |
[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of GRIK5 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GRIN1 |
CTD |
PMID:15139026 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
Sodium Glutamate results in increased expression of GRIN2C mRNA |
CTD |
PMID:11872244 |
|
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
decreases expression increases expression |
EXP |
Sodium Glutamate results in decreased expression of GRIN2D mRNA Sodium Glutamate results in increased expression of GRIN2D mRNA |
CTD |
PMID:11872244 PMID:20928830 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity multiple interactions |
ISO |
Sodium Glutamate results in decreased activity of GSR protein Sodium Glutamate results in increased expression of and results in decreased activity of GSR protein; Tea inhibits the reaction [Sodium Glutamate results in decreased activity of GSR protein] |
CTD |
PMID:25473020 PMID:29679905 PMID:30733785 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Sodium Glutamate results in increased expression of GSTM2 mRNA |
CTD |
PMID:20111022 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
|